ASTX727, Venetoclax, and Gilteritinib
A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation
Arms / Cohorts
Experimental:Phase 1: Decitabine + Cedazuridine + Venetoclax + Gilteritib
Accepting patients
Experimental:Phase 2, Cohort A: Decitabine + Cedazuridine + Venetoclax + Gilteritib
Accepting patients
Experimental:Phase 2, Cohort B: Decitabine + Cedazuridine + Venetoclax + Gilteritib
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.